Aarti Drugs Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: ₹487.50 High: ₹508.05
on August 8, 2025

52 Week Range

Low: ₹312.00 High: ₹635.00
on April 7, 2025
on August 27, 2024

All-Time High: ₹1,026.95 on October 5, 2020

Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights

Key Statistics

Market Cap i INR44.8B
EPS i 20.66
P/E Ratio (TTM) i 23.77
Forward P/E i 15.13
P/B Ratio i 3.28
PEG Ratio i -21.01
Div. Yield i 0.22%
ROE i 12.28%
Beta i 0.206
Debt to Equity i 44.92

Financial Highlights

Profitability

Gross Margin i 36.77%
Operating Margin i 10.11%
Profit Margin i 7.80%

Returns and Earnings

Return on Assets (TTM) i 6.53%
Return on Equity (TTM) i 12.28%
EBITDA i INR3.1B
Net Income (TTM) i INR1.9B

Growth

Revenue (TTM) i
Revenue Per Share (TTM) i INR265.39
Quarterly Revenue Growth (YoY) i 6.30%
Quarterly Earnings Growth (YoY) i 62.20%

Dividend Information

Last 12-Month Dividend i ₹1.00
Current Dividend Yield i 0.22%
3-Year Average Dividend Yield i 0.23%
3-Year Average Annual Dividend i ₹1.00
3-Year Total Dividends i ₹3.00
Ex-Dividend Date i February 4, 2025

Peer Performance Comparison

Performance comparison table showing returns for peer companies over various time periods
CompanyMarket Cap1W1M3M6MYTD1Y3Y5Y
Aarti Drugs AARTIDRUGS 44.83B Small-cap0.47%3.52%17.71%21.40%7.96%-1.73%18.09%-4.28%
Sun Pharmaceutical SUNPHARMA 3.84T Large-cap-2.63%-5.12%-10.20%-8.38%-16.03%-8.55%73.73%198.65%
Divi's Laboratories DIVISLAB 1.63T Large-cap-7.03%-14.75%-0.77%-0.41%-2.61%22.45%58.73%91.42%
Sun Pharma Advanced SPARC 46.34B Small-cap-4.83%-8.86%0.02%-8.70%-28.94%-34.79%-34.46%-20.13%
Sequent Scientific SEQUENT 42.04B Small-cap-0.34%-9.41%8.30%7.32%-9.00%22.29%57.12%26.68%
RPG Life Sciences RPGLIFE 38.76B Small-cap-0.43%-8.96%16.81%-2.37%6.56%7.55%246.33%526.53%

Ownership & Short Interest

Insider Ownership i 60.61%
Institutional Ownership i 10.56%
Shares Short i N/A
Short Ratio i N/A
Short % of Shares Outstanding i N/A
Average 10-Day Volume i 277K
Average 90-Day Volume i 692K

Aarti Drugs Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Aarti Drugs would have performed over time.

INR
If not specified, the latest available data will be used

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

In the last 52 weeks, Aarti Drugs reached a high of ₹635.00 (on August 27, 2024) and a low of ₹312.00 (on April 7, 2025).
Curious about Aarti Drugs's size and valuation? Its market capitalization stands at 44.83B. When it comes to valuation, the P/E ratio (trailing twelve months) is 23.77, and the forward P/E (looking ahead) is 15.13.
Yes, Aarti Drugs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.22%, and the company has paid an average of ₹1.00 per share annually over the past 3 years.

When looking at Aarti Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Sun Pharmaceutical
SUNPHARMA
3.84THealthcareDrug Manufacturers - Specialty & Generic-8.55%73.73%
Divi's Laboratories
DIVISLAB
1.63THealthcareDrug Manufacturers - Specialty & Generic22.45%58.73%
Sun Pharma Advanced
SPARC
46.34BHealthcareDrug Manufacturers - Specialty & Generic-34.79%-34.46%
Sequent Scientific
SEQUENT
42.04BHealthcareDrug Manufacturers - Specialty & Generic22.29%57.12%
RPG Life Sciences
RPGLIFE
38.76BHealthcareDrug Manufacturers - Specialty & Generic7.55%246.33%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

To get a sense of Aarti Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.28%, the Debt to Equity ratio from the most recent quarter is 44.92, and its Gross Profit Margin stands at 36.77%.
Looking at Aarti Drugs's growth, its revenue over the trailing twelve months (TTM) was INR24B. Compared to the same quarter last year (YoY), quarterly revenue grew by 6.30%, and quarterly earnings saw a YoY growth of 62.20%.
Wondering who owns Aarti Drugs stock? Company insiders (like executives and directors) hold about 60.61% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 10.56%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.